Viewing Study NCT01108458


Ignite Creation Date: 2025-12-25 @ 12:10 AM
Ignite Modification Date: 2025-12-25 @ 10:10 PM
Study NCT ID: NCT01108458
Status: TERMINATED
Last Update Posted: 2017-03-03
First Post: 2010-04-20
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Sponsor: George Albert Fisher
Organization: